Kestra Medical Lifts FY27 Revenue Outlook to $141M
KMTS sits 38% above its 52-week low of $17.34 on elevated volume (1.8× avg).
Summary
Kestra Medical raised its FY27 revenue guidance to $141 million, up from the $137 million it guided in July, representing growth of 48% compared to FY26. The company reported Q1 revenue that beat estimates. This follows FY26 revenue of $95.1 million, up 59% year-over-year, and a $200 million debt refinancing. The raised outlook is a modest but positive signal for the company's growth trajectory.
At the time of this announcement, KMTS was trading at $24.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $17.34 to $30.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.